Skip to main content
. 2023 Mar 15;7(13):3225–3231. doi: 10.1182/bloodadvances.2022009323

Table 3.

Salvage regimens before ASCT

Salvage regimen
Brentuximab/bendamustine 26 (39%)
Brentuximab/gemcitabine 15 (22%)
Gemcitabine/vinorelbine 10 (15%)
Ifosfamide/vinorelbine 9 (13%)
Brentuximab 8 (12%)
Ifosfamide/carboplatin/etoposide 6 (9%)
Ifosfamide/gemcitabine/vinorelbine 4 (6%)
Brentuximab/nivolumab 4 (6%)
Gemcitabine/vinblastine/liposomal doxorubicin 1 (1%)
Bendamustine/gemcitabine/vinorelbine 1 (1%)
Other 6 (9%)